One year maintenance of carboplatin in patients with epithelial ovarian cancer - A phase II study

Israel Medical Association Journal

Volumn 8, Issue 1, 2006, Pages 27-29

  Safra, Tamar ^a,b   Kovner, Felix ^a,b   Barak, Nelly ^a,b   Inbar, Moshe J ^a,b   Ron, Ilan G ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Carboplatin; Maintenance chemotherapy; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY; MAINTENANCE THERAPY; OVARY CANCER; PELVIS RADIOGRAPHY; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 30944439146     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Blumenson LE. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 1998;71:190-5.
2. Markman M, Bundy B, Alberts D, et al. Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup trial (GOG, SWOG, ECOG). J Clin Oncol 2001;19:1001-7.
3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
4. Piccart M, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
5. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III and IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
6. Stiff PJ, Veum-Stone J, Lazarus HM, et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med 2000;133:504-15.
7. Levin L, Hryniuk W. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-67.
8. Levin L, Simon R, Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 1993;85:1732-42.
9. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
10. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-5.
11. Bookman MA, Greer BE, Ozols RF: Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 2003;13:735-40.
12. Copeland LJ, Bookman M, Trimble E. Gynecologic Oncology Group Protocol GOG 182-ICON5. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 2003;90:S1-7.
13. Markman M, Liu PY, Wilczynski S, et al. Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-5.